China National Medicines (600511.SS) traded flat 0 % during a 24 hours period ending at 10:09 AM Central Europe on Tuesday 27th. One China National Medicines stock can currently be bought for about CNY 27.81 on popular exchanges. Current supply of China National Medicines stocks is 754.5 mn. China National Medicines has a current market capitalization of CNY 21 bn and approximately CNY 138.2 mn worth of China National Medicines was traded on exchanges in the last 24 hours. Since last month end, China National Medicines has traded 7.16 % up. Simple moving average of last 200 days is at CNY 27.03. The highest price of past 52 weeks was recorded at CNY 31.18 on 11/12/2025. 52 weeks low was at CNY 25.11 on 06/29/2026.

Here is how related stocks have performed in the past 24 hours:

  • Bohai Leasing (000415.SZ) traded flat 0 % and now trades at CNY 4.07. Bohai Leasing has a market capitalisation of CNY 25 bn. Current price/earnings ratio for Bohai Leasing is 12.12.

  • Beijing Tiantan Biological (600161.SS) traded flat 0 % and now trades at CNY 12.44. Beijing Tiantan Biological has a market capitalisation of CNY 25 bn. Beijing Tiantan Biological has a current price to earnings ratio of 33.19.

  • Xiamen C & D (600153.SS) traded flat 0 % and now trades at CNY 8.63. Current market capitalisation for Xiamen C & D is CNY 25.1 bn.

  • Pangang Vanadium Tit (000629.SZ) traded flat 0 % and now trades at CNY 2.65. Current market capitalisation for Pangang Vanadium Tit is CNY 25 bn. Pangang Vanadium Tit has a current price to earnings ratio of 76.14.

  • Hainan Jinpan Smart Techno (688676.SS) traded flat 0 % and now trades at CNY 48.75. Current market capitalisation for Hainan Jinpan Smart Techno is CNY 24.8 bn. Current price/earnings ratio for Hainan Jinpan Smart Techno is 33.84. A recent ESG assessment released by a registered rating agency evaluated the performance of companies listed in Hainan’s A‑share market for 2025. The report noted that a number of firms improved their standing, with several moving up to the top tier of the rating scale, while a few saw declines. It highlighted that state‑controlled enterprises generally achieved higher ratings, whereas privately held companies lagged behind, reflecting differences in disclosure practices. The assessment also pointed out that larger companies, particularly those with market values above a certain threshold, were more likely to provide comprehensive ESG disclosures. In industry terms, resource‑intensive sectors such as power equipment and steel showed stronger ESG foundations, whereas sectors like consumer goods and textiles scored lower. The study emphasized that while overall ESG performance has improved, many firms still need to deepen their focus on environmental and social metrics and move beyond mere compliance toward genuine value creation.

About China National Medicines

China National Medicines Corp. Ltd. is a health care provider and service company that wholesales and retails chemical material medicines, Western medicine preparations, biochemical medicines, biological products, and Chinese traditional medicines through its subsidiaries, which also manufactures pharmaceuticals including injections, capsules, tablets, and other related products under the CNCM brand name.